References
- Stein DG , GeddesRI, SribnickEA. Critical Developments in Clinical Trials for the Treatment of Traumatic Brian Injury. In: Handbook of Clinical Neurology, Traumatic Brain Injury Part 1 (Volume 127). GrafmanJ, SalazarAM ( Eds). Elsevier, NY, USA, 433–451 (2015).
- Wright DW , YeattsSD, SilbergleitRet al. Very early administration of progesterone for acute traumatic brain injury. N. Engl. J. Med.371(26), 2457–2466 (2014).
- Skolnick BE , MaasAI, NarayanRKet al. A clinical trial of progesterone for severe traumatic brain injury. N. Engl. J. Med.371(26), 2467–2476 (2014).
- Schwamm LH . Progesterone for traumatic brain injury – resisting the sirens’ song. N. Engl. J. Med.371(26), 2522–2523 (2014).
- Jickling GC , SharpFR. Improving the translation of animal ischemic stroke studies to humans. Metab. Brain Dis.30(2), 461–467 (2014).
- Garner JP . The significance of meaning: why do over 90% of behavioral neuroscience results fail to translate to humans, and what can we do to fix it?ILAR J.55(3), 438–456 (2014).
- Gultekin R , HuangS, ClavisiO, PattuwageL, KonigTC, GruenR. Pharmacological interventions in traumatic brain injury: can we rely on systematic reviews for evidence?Injury doi:10.1016/j.injury (2015) ( Epub ahead of print).
- Stein DG . On improving human clinical trials to the level of animal ischemic stroke studies. Metab. Brain Dis.30, 469–471 (2014).
- Schumacher M , DenierC, OudinetJ-P, AdamsDH, GuennounR. Progesterone neuroprotection: the background of clinical trial failure. J. Steroid Biochem. Mol. Biol. doi:10.1016/j.jsbmb.2015.11.010 (2015) ( Epub ahead of print).
- Howard RB , SayeedI, SteinD. Suboptimal dosing parameters as possible factors in the negative Phase III clinical trials of progesterone in TBI. J. Neurotrauma doi:10.1089/neu.2015.4179 (2015) ( Epub ahead of print).
- Wali B , IshratT, WonS, SteinDG, SayeedI. Progesterone in experimental permanent stroke: a dose-response and therapeutic time-window study. Brain137(Pt 2), 486–502 (2014).
- Yousuf S , AtifF, SayeedI, TangH, SteinDG. Progesterone in transient ischemic stroke: a dose-response study. Psychopharmacology (Berl.)231(17), 3313–3323 (2014).
- McCord JM . Superoxide dismutase, lipid peroxidation, and bell-shaped dose response curves. Dose Response6(3), 223–238 (2008).
- Reynolds AR . Potential relevance of bell-shaped and U-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer. Dose Response8(3), 253–284 (2010).
- Owen SC , DoakAK, GaneshANet al. Colloidal drug formulations can explain “bell-shaped” concentration-response curves. ACS Chem. Biol.9(3), 777–784 (2014).
- Sharma V , McNeillJH. To scale or not to scale: the principles of dose extrapolation. Br. J. Pharmacol.157(6), 907–921 (2009).
- Herring JM , McMichaelMA, CorsiR, WurlodV. Intravenous lipid emulsion therapy in three cases of canine naproxen overdose. J. Vet. Emerg. Crit. Care (San Antonio)25(5), 672–678 (2015).
- Lee HM , ArcherJR, DarganPI, WoodDM. What are the adverse effects associated with the combined use of intravenous lipid emulsion and extracorporeal membrane oxygenation in the poisoned patient?Clin. Toxicol. (Phila.)53(3), 145–150 (2015).
- Taftachi F , Sanaei-ZadehH, SepehrianB, ZamaniN. Lipid emulsion improves Glasgow Coma Scale and decreases blood glucose level in the setting of acute non-local anesthetic drug poisoning – a randomized controlled trial. Eur. Rev. Med. Pharmacol. Sci.16(Suppl. 1), 38–42 (2012).
- Manzanares W , DhaliwalR, JurewitschB, StapletonRD, JeejeebhoyKN, HeylandDK. Alternative lipid emulsions in the critically ill: a systematic review of the evidence. Intens. Care Med.39(10), 1683–1694 (2013).
- Roozenbeek B , LingsmaHF, MaasAI. New considerations in the design of clinical trials for traumatic brain injury. Clin. Investig. (Lond.)2(2), 153–162 (2012).
- Shukla P , RaoGM, PandeyG, SharmaS, MittapellyNet al. Therapeutic interventions in sepsis: current and anticipated pharmacological agents. Br. J. Pharmacol.171(22), 5011–5031 (2014).
- NIH Toolbox® . www.nihtoolbox.org/Pages/default.aspx.
- Green SM . Cheerio, laddie! Bidding farewell to the Glasgow Coma Scale. Ann. Emerg. Med.58(5), 427–430 (2011).
- Lingsma HF , RoozenbeekB, LiBet al. Large between-center differences in outcome after moderate and severe traumatic brain injury in the International Mission on Prognosis and Clinical Trial Design in Traumatic Brain Injury (IMPACT) study. Neurosurgery68(3), 601–607 (2011).
- Kruschke JK . What to believe: Bayesian methods for data analysis. Trends Cogn. Sci.14(7), 293–300 (2010).
- Dragalin V . An introduction to adaptive designs and adaptation in CNS trials. Eur. Neuropsychopharmacol.21(2), 153–158 (2011).
- Jang SH , YanZG, LazorJA. Therapeutic drug monitoring: a patient management tool for precision medicine. Clin. Pharmacol. Ther. doi:10.1002/cpt.298 (2015) ( Epub ahead of print).
- Duffy DJ . Problems, challenges and promises: perspectives on precision medicine. Brief Bioinform. doi:10.1093/bib/bbv060 (2015) ( Epub ahead of print).
- Cekic M , CutlerSM, VanLandinghamJW, SteinDG. Vitamin D deficiency reduces the benefits of progesterone treatment after brain injury in aged rats. Neurobiol. Aging32(5), 864–874 (2011).
- Margulies S , HicksR. Combination therapies for traumatic brain injury: prospective considerations. J. Neurotrauma26(6), 925–939 (2009).
- Geschwind N . Late changes in the nervous system: an overview. In: Plasticity and Recovery of Function in the Central Nervous System. SteinDG, RosenA, ButtersN ( Eds). Academic Press, NY, USA, 467–508 (1974).